跳至主要内容
临床试验/NCT04318431
NCT04318431已完成不适用

Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.

Centre Hospitalier Intercommunal Creteil44 个研究点 分布在 1 个国家目标入组 605 人开始时间: 2020年4月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
605
试验地点
44
主要终点
Proportion of asymptomatic children or children with mild respiratory symptoms

研究概览

简要总结

This study is expected to provide, for the first time, data on Cov2-SARS circulation in asymptomatic children and children with moderate respiratory symptoms in order to construct the severity pyramid of this novel pathogen. This information will be essential in the coming weeks to understand the dynamics of the transmission of this pathogen at the population level and to highlight the relevance of public health interventions, particularly with regard to the systematic closure of schools and childcare facilities.

详细描述

Cov2-SARS is an emerging respiratory virus of the coronavirus family responsible for a global epidemic since November 2019. As of March 10, 2020, it had caused more than 160,000 cases of corona virus disease (COVID-19), including more than 6,500 deaths worldwide. France is one of the main epidemic outbreaks with more than 5,000 confirmed cases and the number of diagnosed patients is increasing every day.

The number of confirmed paediatric cases is relatively low, and the mortality rate in children is close to zero. This contrast suggests that children are more likely to present pauci-symptomatic or even asymptomatic forms of the disease, which are therefore undiagnosed in most cases. Given the rapid spread of this virus, and the fact that indigenous cases without an obvious chain of transmission now appear to be frequent in France, it is possible that the pauci-symptomatic or asymptomatic child may play a role in the transmission of the pathogen and the dynamics of the epidemic, as documented for other respiratory pathogens such as influenza. Based on this hypothesis, the closure of children's communities has been organized in France and other highly endemic countries.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
— 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Asymptomatic children:
  • Age between birth and 15 years
  • Carrying out a visit within the framework defined by the learned societies and professional organisations representative of paediatrics in France, i.e. :
  • The consultation of the first month and all consultations involving compulsory vaccinations (2, 4, 5, 11, 12, 16 months).
  • Consultations for acute pathologies, infectious or not.
  • Monitoring of chronic diseases that warrant clinical examination (the majority of which can be carried out by telemedicine) or in the case of acute exacerbation.
  • In one of the participating outpatient centres
  • During the study period
  • With a clinical examination that does not reveal any progressive infectious pathology
  • AND Pauci-symptomatic children
  • Age between birth and 15 years,
  • Consultant at one of the participating outpatient centres
  • During the study period
  • And presenting with a mild respiratory infection:
  • Rhinopharyngitis, Acute otitis media, Angina, Bronchitis, etc.
  • Acceptance to participate in the protocol by one of the holders of parental authority
  • Affiliated to a social security

排除标准

  • Refusal to participate in the study

结局指标

主要结局

Proportion of asymptomatic children or children with mild respiratory symptoms

时间窗: 14 days

Proportion of asymptomatic children or children with mild respiratory symptoms (mildly-symptomatic children) with a positive SARS-Cov2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on rhino pharyngeal swab or/and IgM/IgG positive serology in the Ile-de-France region during an epidemic period.

次要结局

  • Confirmed Cov2-SARS cases by symptoms(14 days)
  • Viral load(14 days)
  • Other respiratory viruses(14 days)
  • Sars-Cov2 IgM(14 days)
  • Confirmed Cov2-SARS cases by age(14 days)
  • Sars-Cov2 IgG(14 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (44)

Loading locations...

相似试验

Prevalence of SARS -Cov2 Carriage in Asymptomatic... | 临床试验